{
    "eu_aut_status": "ACTIVE",
    "eu_brand_name_current": "Dasatinib Accordpharma",
    "status_type": "a",
    "eu_pnumber": "EU/1/21/1541",
    "active_substance": "dasatinib",
    "eu_mah_current": "Accord Healthcare S.L.U.",
    "atc_code": "L01EA02",
    "orphan_status": "h",
    "eu_aut_date": "2022-03-24",
    "eu_aut_type_initial": "standard",
    "eu_aut_type_current": "standard",
    "ema_number": "EMEA/H/C/005317",
    "ema_number_id": "5317",
    "eu_referral": "False",
    "eu_suspension": "False",
    "ema_number_certainty": "1.0",
    "authorisation_row": "0",
    "scrape_date_web": "2023-01-07",
    "filedates": {
        "EU-1-21-1541_h_dec_0.pdf": {
            "pdf_link": "https://ec.europa.eu/health/documents/community-register/2022/20220324154987/dec_154987_en.pdf",
            "pdf_date": "2022-03-24",
            "pdf_scrape_date": "2023-01-07"
        },
        "EU-1-21-1541_h_anx_0.pdf": {
            "pdf_link": "https://ec.europa.eu/health/documents/community-register/2022/20220324154987/anx_154987_en.pdf",
            "pdf_date": "2022-03-24",
            "pdf_scrape_date": "2023-01-07"
        },
        "EU-1-21-1541_h_public-assessment-report.pdf": {
            "pdf_link": "https://www.ema.europa.eu/documents/assessment-report/dasatinib-accordpharma-epar-public-assessment-report_en.pdf",
            "pdf_date": "2023-01-07",
            "pdf_scrape_date": "2023-01-07"
        },
        "EU-1-21-1541_h_epar-other_0.pdf": {
            "pdf_link": "https://www.ema.europa.eu/documents/procedural-steps-after/dasatinib-accordpharma-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf",
            "pdf_date": "2023-01-07",
            "pdf_scrape_date": "2023-01-07"
        }
    }
}